Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about a paper he co-authored with colleagues published in Annals of Oncology:
“Cancer clinical trials are the foundation for medical advances in oncology.
Despite ongoing skepticism about their direct benefits to participants, we argue that the best management for most patients with incurable cancer is on a clinical trial.
Our viewpoint published in ESMO flagship journal Annals of Oncology is rooted in the multifaceted advantages that clinical trials offer not only to the broader medical community and to future patients with cancer, but also to the individuals who participate.”
Title: The best management for most patients with incurable cancer is on a clinical trial
Authors: V. Subbiah, R. Kurzrock
You can read the full article in ESMO Open.
More posts featuring Vivek Subbiah.